Zurich Cantonal Bank’s AbCellera Biologics ABCL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-2,633
Closed -$9.01K 2551
2025
Q4
$9.01K Hold
2,633
﹤0.01% 2490
2025
Q3
$13.2K Sell
2,633
-1,156
-31% -$5.09K ﹤0.01% 2487
2025
Q2
$13K Sell
3,789
-416
-10% -$1.04K ﹤0.01% 2505
2025
Q1
$9.38K Buy
+4,205
New +$12.1K ﹤0.01% 2594

Other funds holding ABCL

Zurich Cantonal Bank's ABCL Position: Q1 2026 in Review

Zurich Cantonal Bank sold out of AbCellera Biologics (ABCL) in Q1 2026, closing a stake of 2,633 shares — an estimated $9.01K sold.

Zurich Cantonal Bank first reported a position in ABCL in Q1 2025 and held it in 4 quarters. The position peaked at $13.2K in Q3 2025. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

  • Zurich Cantonal Bank reported no remaining AbCellera Biologics position as of Q1 2026 after selling out during the quarter.
  • Zurich Cantonal Bank sold 2,633 AbCellera Biologics shares in Q1 2026, an estimated $9.01K.
  • Zurich Cantonal Bank first reported a position in AbCellera Biologics in Q1 2025 and held it in 4 quarters.
  • Zurich Cantonal Bank's AbCellera Biologics position peaked at $13.2K in Q3 2025.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on Zurich Cantonal Bank's 13F filing for Q1 2026, filed 15 May 2026.